BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Growing Uptake of Genzyme Corporation (GENZ)'s Aubagio at Three Months Post-Launch Is Likely Driven by Perceived Product Convenience Even As Neurologists Search to Identify Appropriate Candidates, According to a Recent BioTrends Report


3/6/2013 8:32:39 AM

EXTON, Penn., March 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that 34 percent of surveyed U.S. neurologists have prescribed Genzyme's Aubagio to at least one of their multiple sclerosis (MS) patients at three months post-launch, a significant increase in trial rate from one month post-launch (16 percent). Data from the recently published LaunchTrends®: Aubagio Wave 2 report suggest that expanding Aubagio trial is driven in part by positive perceptions related to the product's convenient once-daily, oral administration. Aubagio, the second oral disease-modifying agent (DMA) to reach the MS market, is the DMA most associated with favorable route of administration/formulation by half of neurologists. Despite the growth in Aubagio prescriber base, Aubagio's current DMA-treated relapsing remitting MS (RRMS) share and average patient volume per prescriber remain low, likely owing to neurologists' continued search to identify appropriate Aubagio candidates, as well as lingering concerns related to hepatotoxicity and teratogenicity. Nevertheless, adoption within individual practices is largely on par with that seen for Novartis's Gilenya, the first oral DMA to reach the MS market, three months after Gilenya's commercial availability*.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

Over the next six months, surveyed neurologists anticipate that Aubagio's DMA-treated RRMS share will increase significantly to over 6 percent, pulling share from Biogen Idec's Avonex, Bayer HealthCare's Betaseron, Teva's Copaxone and Pfizer/EMD Serono's Rebif. In fact, of the two-thirds of neurologists who have never prescribed Aubagio, 69 percent anticipate a trial within the next six months, suggesting Aubagio prescriber base will grow to approximately 80 percent of neurologists by nine months post-launch. High product satisfaction among current prescribers, as well as continued messaging and physician and patient education, will likely contribute to future growth.

LaunchTrends: Aubagio is a four-wave syndicated report series that specifically tracks the introduction of Aubagio into the market, based on data collected at one month, three months, six months and one year post-commercial availability of Aubagio from primary research with neurologists. The second wave was fielded January 11-14, 2013 with 73 U.S. neurologists followed by qualitative interviews with a subset of 15 survey respondents. Along with awareness and sources of familiarity, the reports assess neurologists' trial, adoption and usage, including anticipated future trends, of Aubagio within the MS market. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Genzyme's promotional efforts and benchmarking against other previously launched MS agents.

In addition to the LaunchTrends: Aubagio report series, BioTrends will track the U. S. uptake of Aubagio in the biannual TreatmentTrends®: Multiple Sclerosis (US) report series. This syndicated primary research report series provides a view of the broader MS market landscape, including all currently approved DMAs and DMAs in late-stage clinical development.

*Source: LaunchTrends: Gilenya Wave 2, BioTrends Research Group, published February 11, 2011

About BioTrends Research Group BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->